G protein-coupled receptor
Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes
The UK is the first country in Europe to authorise the oral medication
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer
Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually
Lilly to acquire AtaiBeckley in deal worth $2.8bn
The acquisition will advance therapies for treatment-resistant depression and other mental health conditions
Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis
This new option for patients allows for as few as six maintenance injections per year
Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn
The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease
Lilly and UNICEF collaborate to improve non-communicable disease prevention
Six-year initiative to improve NCD prevention and care for children in low- and middle-income countries
Lilly commits additional $4.5bn for US manufacturing sites
The company has also opened its first dedicated genetic medicine facility in Indiana in the US
Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn
The acquisition will help Lilly to expand its capabilities in cell and gene therapy
AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment
The agreement covers the development of new lead tau morphomer candidates
Lilly to acquire Centessa in deal worth up to $7.8bn
The companies aim to advance treatments for narcolepsy and other sleep-wake disorders
Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss
Taken at any time of the day, the oral GLP-1 is the only pill to have no food or water restrictions